Autoimmune disease Archives

News and Trends 2 May 2023

Cabaletta Bio’s lupus drug cleared for trial

Cabaletta Bio, Inc., a U.S. clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to CABA-201. Cabaletta Bio’s CABA-201 is a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, designed […]

May 2, 2023 - 3 minutesmins - By Jim Cornall

In Depth 3 Mar 2023

Let’s Take a Closer Look at 7 Autoimmune Diseases Biotechs are Fighting to Treat

While we mostly think of disease as being caused by bacteria or viruses, an illness can often occur when the body’s own defenses turn against itself. Here we’ll take a look at seven rare autoimmune diseases you may not have heard of and what biotechs are doing to treat them. The body’s immune system can […]

March 3, 2023 - 8 minutesmins - By Alexander Burik

News and Trends 16 Feb 2023

Maxion Therapeutics raises $16M to target GPCRs

Biotechnology company Maxion Therapeutics has completed its $16 million Series A financing. The funds will be used to support the development of novel biologics targeting ion channels and G-protein-coupled receptors (GPCRs) via Maxion’s proprietary, patent-protected KnotBody platform. Ion channels and GPCRs are critical cell surface proteins involved in a wide range of previously untreatable or […]

February 16, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 7 Feb 2023

Certa scleroderma study shows improvement in more than 60% of patients

Certa Therapeutics has announced what it says are ground-breaking clinical trial data for FT011, its novel therapy for the treatment of serious inflammatory and fibrotic diseases. Certa Therapeutics has recently completed a global phase 2, multi-centre, randomized, double blind, placebo-controlled study of the pharmacokinetics, pharmacodynamic effects, and safety, of oral FT011 in patients with scleroderma. […]

February 7, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 4 Jan 2023

Aditxt forms Adimune to focus on immune modulation therapies

Aditxt, Inc., a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has formed a U.S.-based subsidiary Adimune, Inc. The plan is to submit a clinical trial application (CTA) for its immunotherapeutic technology drug candidate, ADI-100 (ADI). The CTA will request approval for Adimune to conduct the […]

January 4, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 18 Nov 2022

Sanofi’s Enjaymo for hemolytic anemia given marketing authorization by EC

Sanofi’s treatment, Enjaymo, for hemolytic anemia in adult patients with cold agglutinin disease (CAD), has been granted marketing authorization by the European Commission (EC). Enjaymo is the first and only approved therapeutic option for the rare, serious and chronic autoimmune disease where the body mistakenly attacks healthy red blood cells and causes their rupture, known […]

November 18, 2022 - 4 minutesmins - By Liza Laws

More News! 14 Nov 2022

BioSenic’s autoimmune disease platform adapting to meet unmet medical needs

BioSenic’s systemic autoimmune disease platform, originally designed by Medsenic, is now developing controlled dosages and new formulations adapted to a significant number of important indications with unmet medical needs. BioSenic specializes in serious autoimmune and inflammatory diseases as well as cell repair. The update follows the announcement of the merger between Bone Therapeutics and Medsenic […]

November 14, 2022 - 4 minutesmins - By Liza Laws

News and Trends 8 Nov 2022

Rallybio announces positive phase 1 results for drug treating PNH and gMG

Affibody’s licensee Rallybio Corporation has announced positive topline results from a phase 1 single ascending dose (SAD) study in healthy participants of RLYB116. RLYB116 is a novel, potentially long-acting, subcutaneously administered inhibitor of complement factor 5, or C5, in development for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (gMG). […]

November 8, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 1 Nov 2022

Human Immunology Biosciences launches with $120M

Human Immunology Biosciences (HI-Bio), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), announced its launch with $120 million in financing. HI-Bio was incubated by ARCH Venture Partners and Monograph Capital, joined by Jeito Capital and unnamed institutional investors and family offices. Few targeted therapies exist for the autoimmune, allergic […]

November 1, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 26 Oct 2022

First patient dosed in trial to assess predictive performance of immuno-oncology therapy

The first patient has been dosed at the Macquarie University Hospital in Sydney as part of a clinical trial to evaluate whether a drug can predict patient response to immuno-oncology therapy targeting a number of solid tumor types. ImaginAb Inc. is a biotech company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and next generation […]

October 26, 2022 - 3 minutesmins - By Liza Laws

lupus autoimmune disease neutrophil citryll

News and Trends 26 Oct 2022

Partnership for better understanding of Sjögren’s syndrome announced by Evotec

A molecular patient database for Sjögren’s syndrome (SjS) and systemic lupus erythematosus (SLE) is to be generated following a partnership between Evotec SE and a German university. Evotec made the announcement yesterday (Tuesday) that it will work with Hannover Medical School (MHH). The strategic partnership between Evotec and MHH aims at achieving a better understanding […]

October 26, 2022 - 3 minutesmins - By Liza Laws

News and Trends 19 Oct 2022

Nucleome Therapeutics raises £37.5M to deliver precision medicines

U.K. biotech company Nucleome Therapeutics Limited has closed an oversubscribed £37.5 million ($42.4 million) series A financing round. The funds will be used to advance the company’s autoimmune disease programs, fuel expansion of its dark genome atlas and further develop its pioneering platform. The financing was led by new investor M Ventures, the strategic, corporate […]

October 19, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Autoimmune disease

Cabaletta Bio’s lupus drug cleared for trial

Let’s Take a Closer Look at 7 Autoimmune Diseases Biotechs are Fighting to Treat

Maxion Therapeutics raises $16M to target GPCRs

Certa scleroderma study shows improvement in more than 60% of patients

Aditxt forms Adimune to focus on immune modulation therapies

Sanofi’s Enjaymo for hemolytic anemia given marketing authorization by EC

BioSenic’s autoimmune disease platform adapting to meet unmet medical needs

Rallybio announces positive phase 1 results for drug treating PNH and gMG

Human Immunology Biosciences launches with $120M

First patient dosed in trial to assess predictive performance of immuno-oncology therapy

Partnership for better understanding of Sjögren’s syndrome announced by Evotec

Nucleome Therapeutics raises £37.5M to deliver precision medicines

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!